Skip to main content
KYORIN Pharmaceutical Co., Ltd. logo

KYORIN Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 4569 ISIN · JP3247090008 T Manufacturing
Open in API
Filings indexed 60 across all filing types
Latest filing 2026-05-20 Notice of Dividend Amou…
Country JP Japan
Listing T 4569

About KYORIN Pharmaceutical Co., Ltd.

https://www.kyorin-pharm.co.jp/en/

KYORIN Pharmaceutical Co., Ltd. is a research-based pharmaceutical company engaged in the research, development, manufacturing, and sale of prescription (ethical) and generic drugs. The company's commercial and R&D activities are focused on key therapeutic areas, including respiratory medicine, urology, otolaryngology (ENT), and inflammatory bowel disease (IBD). Through its subsidiaries, such as KYORIN Rimedio Co., Ltd., it also handles the manufacturing and distribution of generic medicines. The company is committed to providing a stable supply of high-quality pharmaceutical products to medical institutions and patients.

Recent filings

Filing Released Lang Actions
剰余金の配当に関するお知らせ
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement by 杏林製薬株式会社 detailing the board resolution to pay a dividend for the fiscal year ending March 31, 2026. It specifies the per-share dividend amount, total dividend outlay, record date, payment date, and breakdown of interim and year-end dividends. This matches the criteria for a Notice of Dividend Amount (Code: DIV).
2026-05-20 Japanese
後発医薬品事業の承継に向けた基本合意に関するお知らせ
Regulatory Filings
2026-04-24 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a previously filed semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. H1 68
2025-11-13 Japanese
半期報告書－第68期(2025/04/01－2025/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (半期報告書) filed by Kyorin Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MDA), and audit review information for the interim period ending September 30, 2025. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2025
2025-11-13 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act following the resolution of the '第67回定時株主総会' (67th Annual General Meeting). Section 2 details the resolutions passed, specifically the election of six directors, and provides the voting results (votes for, against, abstentions, and approval percentages). This content—reporting the results of a shareholder vote following an AGM—directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the core purpose is reporting the *results* of the vote, not providing the meeting materials (AGM-R) or proxy information (PSI).
2025-06-26 Japanese
内部統制報告書－第67期(2024/04/01－2025/03/31)
Governance Information Classification · 100% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly references the legal basis as "金融商品取引法第24条の４の４第１項" (Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act). It details the scope, criteria, and procedures for evaluating internal controls over financial reporting as of the fiscal year-end (March 31, 2025), concluding that the internal controls are effective. This structure and content precisely match the requirements for an Internal Control Report, which is often filed alongside the Annual Report (10-K) but is a distinct regulatory filing in Japan. Given the specific Japanese regulatory context and the document's focus on internal control assessment, the closest equivalent category among the provided definitions is 'Audit Report / Information' (AR), as it covers internal/regulatory stress tests and applied accounting principles/reports, although 'Internal Control Report' is a specific type of assurance report. However, since there is no specific code for 'Internal Control Report' (J-SOX), and it is a formal report on internal controls, AR is the most appropriate fit among the choices, as it covers standalone audit/assurance reports. The document is the report itself, not an announcement of the report.
2025-06-19 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.